Search research articles
Contact Us
Filters
Showing results (91-100 of 175) with videos related to
Page
of 18
Sort By:
HIV Clinical Trials
|
February 2, 2013
Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial
Anna Maria Geretti, Jose R Arribas, Erkki Lathouwers, et al.
Antimicrobial Agents and Chemotherapy
|
November 4, 2025
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection
Anna Maria Geretti, Alexandre Sostelly, Simon Buatois, et al.
BMC Infectious Diseases
|
January 28, 2025
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance
Drieda Zaçe, Albiana Çekrezi, Christopher Jones, et al.
BMC Infectious Diseases
|
July 22, 2020
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Collins C Iwuji, Duncan Churchill, Stephen Bremner, et al.
The Lancet. Global Health
|
September 16, 2017
Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis
Alexander J Stockdale, Mas Chaponda, Apostolos Beloukas, et al.
BMJ Open
|
August 7, 2019
Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis
Laure Lacoin, Michael Hurst, Nathan R Hill, et al.
AIDS (London, England)
|
February 8, 2011
The impact of HIV drug resistance testing on changes to treatment
Loveleen Bansi, Colette Smith, Andrew Phillips, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 17, 2010
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
Loveleen Bansi, Anna Maria Geretti, David Dunn, et al.
The Journal of Infection
|
November 16, 2010
Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care
Aysha Begum Khanom, Charlotte Velvin, Khidir Hawrami, et al.
Antiviral Therapy
|
May 11, 2011
Predicting antiretroviral drug resistance from the latest or the cumulative genotype
Federico Garcia, Marta Alvarez, Zoe Fox, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 175) with videos related to
Sort By:
Page
of 18
HIV Clinical Trials
|
February 2, 2013
Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial
Anna Maria Geretti, Jose R Arribas, Erkki Lathouwers, et al.
Antimicrobial Agents and Chemotherapy
|
November 4, 2025
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection
Anna Maria Geretti, Alexandre Sostelly, Simon Buatois, et al.
BMC Infectious Diseases
|
January 28, 2025
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance
Drieda Zaçe, Albiana Çekrezi, Christopher Jones, et al.
BMC Infectious Diseases
|
July 22, 2020
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Collins C Iwuji, Duncan Churchill, Stephen Bremner, et al.
The Lancet. Global Health
|
September 16, 2017
Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis
Alexander J Stockdale, Mas Chaponda, Apostolos Beloukas, et al.
BMJ Open
|
August 7, 2019
Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis
Laure Lacoin, Michael Hurst, Nathan R Hill, et al.
AIDS (London, England)
|
February 8, 2011
The impact of HIV drug resistance testing on changes to treatment
Loveleen Bansi, Colette Smith, Andrew Phillips, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 17, 2010
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
Loveleen Bansi, Anna Maria Geretti, David Dunn, et al.
The Journal of Infection
|
November 16, 2010
Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care
Aysha Begum Khanom, Charlotte Velvin, Khidir Hawrami, et al.
Antiviral Therapy
|
May 11, 2011
Predicting antiretroviral drug resistance from the latest or the cumulative genotype
Federico Garcia, Marta Alvarez, Zoe Fox, et al.
Page
of 18